{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T14:52:10Z","timestamp":1686927130485},"reference-count":27,"publisher":"Consilium Medicum","issue":"4","license":[{"start":{"date-parts":[[2017,4,15]],"date-time":"2017-04-15T00:00:00Z","timestamp":1492214400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-\u03b1 (TNF\u03b1) inhibitors during a year. Subjects and methods. Examinations were made in 30 patients (22 (73.3%) men) aged 38.35\u00b19.19 years with AS (modified New-York criteria, BASDAI \u22654.0; AS duration, 11.4\u00b19.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1\u00b17.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg\/kg body weight during a year according to the recommended regimen. BASDAI and ASDAS were calculated; C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and TNF\u03b1 and IL-17A concentrations were measured before and 52\u00b12 weeks after TNF\u03b1 inhibitors treatment. BASDAI\/ASDAS improvement, ESR and CRP decreases; ASAS20\/40 responses, ASAS partial remission, and an ASDAS improvement were estimated. Results. In the patients with AS, the concentrations of TNF\u03b1 and IL-17A were higher than those in the healthy individuals (p &lt; 0.000). Twelve (40%) AS patients treated with TNF\u03b1 inhibitors achieved ASAS partial remission. The average estimated back pain, ASDAS and BASDAI scores, and CRP and ESR substantially reduced (p<\/jats:p>","DOI":"10.17116\/terarkh201789480-85","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T16:30:18Z","timestamp":1493397018000},"page":"80-85","source":"Crossref","is-referenced-by-count":3,"title":["Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-\u03b1 inhibitors during a year"],"prefix":"10.26442","volume":"89","author":[{"given":"I Z","family":"Gaydukova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A P","family":"Rebrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A V","family":"Aparkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E V","family":"Khondkaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2017,4,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14412\/1995-4484-2015-657-660"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203860"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1039514"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology(Oxford). 2007;46(9):1450-1453.","DOI":"10.1093\/rheumatology\/kem166"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24001"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.","DOI":"10.1002\/art.1780270401"},{"key":"ref8","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-2291."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"ref12","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-2285."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. AnnRheumDis. 2003;62(2):127-132.","DOI":"10.1136\/ard.62.2.127"},{"key":"ref14","unstructured":"\u0420\u0435\u0431\u0440\u043e\u0432\u0430 \u041e.\u042e., \u0440\u0435\u0434. \u0412 \u043a\u043d: \u0420\u0435\u0431\u0440\u043e\u0432\u0430 \u041e.\u042e. \u0421\u0442\u0430\u0442\u0438\u0441\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u043d\u0430\u043b\u0438\u0437 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0445 \u0434\u0430\u043d\u043d\u044b\u0445. \u041f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u0435 \u043f\u0430\u043a\u0435\u0442\u0430 \u043f\u0440\u0438\u043a\u043b\u0430\u0434\u043d\u044b\u0445 \u043f\u0440\u043e\u0433\u0440\u0430\u043c\u043c STATISTICA. \u041c.: \u041c\u0435\u0434\u0438\u0430-\u0421\u0444\u0435\u0440\u0430; 2002."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/ar3431"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0949-6"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8522-7"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.886351"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.85"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12670"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S105263"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3350-6"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0949-6"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207544"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32229\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T23:15:37Z","timestamp":1634080537000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/32229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,15]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,15]]}},"URL":"https:\/\/doi.org\/10.17116\/terarkh201789480-85","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4,15]]}}}